EAGAN, Minn. & FRESNO, Calif.—Cypress
Systems and Biothera Inc. reached a settlement in a patent infringement suit
filed by Biothera in early 2005 in Minnesota federal district court. Under terms
of the settlement, Cypress will stop selling beta-glucan, will assign its “Beta
Precise” trademark to Biothera, and acknowledge the validity of Biothera’s
patents covering beta-glucan dietary supplements. Biothera holds more than 40
U.S. patents and patents pending covering the right to manufacture and sell
yeast beta-glucan as a dietary supplement.
Richard Mueller, president and chief executive officer (CEO)
of Biothera (www.biotherapharma.com), said, “[The settlement] adds clarity to
the market for beta-glucan products, provides Biothera with new sales and
further strengthens our position in two pending patent infringement lawsuits.”
Those lawsuits, against Biotec Pharmacon ASA and Fenchem Enterprises Ltd., were
filed in March 2005 and are still pending.
For more information on Cypress Systems, visit
www.cypsystems.com or Booth #8072 at SupplySide West.
Email this article
Add a comment
Printer version
Order reprints
RSS Feed
Bookmark article